Clostridium difficile-associated diarrhea from a general hospital in Argentina

• Published in: Anaerobe Vol. 9; no. 3; pp. 113 - 116
• Main Authors: Legaria, M.C, Lumelsky, G, Rosetti, S
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-06-2003
• Subjects: Antibiotic-associated diarrhea; Clostridium difficile; Antibiotic-associated diarrhea; Clostridium difficile
• ISSN: 1075-9964; 1095-8274
• DOI: 10.1016/S1075-9964(03)00088-X

Clostridium difficile is responsible for 15–25% of all cases of antibiotic associated diarrhea. The incidence of infection with this organism is increasing in hospitals worldwide, consequent to the widespread use of broad-spectrum antibiotics. Although the clinical and financial impact of nosocomial
C. difficile infection is believed to be significant, only limited information is available on the importance of
C. difficile as a cause of diarrhea in Argentina. The aim of the study was to evaluate the impact and diagnosis methods of CDAD from symptomatic patients in a general hospital from Argentina.
Consecutive diarrheal stool samples from symptomatic patients from a General Hospital in Argentina were screened for toxigenic
C. difficile between April 2000 and April 2001. Toxins were detected in stools by the Premier Cytoclone A+B EIA. Each specimen was examined for toxigenic
C. difficile strains by culture.
From 104 specimens, 40 (38.5%) [32 of 87 patients (36.8%)] were positive and 64 (61.5%) [55 of 87 patients (63.2%)] were negative by stool toxin assay and/or toxigenic culture. In 11 of 40 positives samples
C. difficile toxins were detected only by toxigenic culture. Five (15.6%) patients presented with symptomatic recurrences. Toxin-negative strains were not isolated. This data indicates that the high prevalence of toxigenic strains of
C. difficile is of concern in routine diagnostic testing for
C. difficile toxins in our study population. Detection of toxins in stools by EIA, coupled with testing strains for toxigenicity only in those cases in which direct toxin assay produces negative results, may be a satisfactory strategy. CDAD is an emerging nosocomial problem in our hospital. It will be necessary to evaluate the epidemiology and measures to control nosocomial spread.